Biological effects of contaminants: Stress on Stress (SoS) response in mussels

The SoS biomarker provides evidence of the effects of pollutants at the whole organism response level. It shows a typical dose-response curve, characterized by a continuous decrease of the parameter LT50 (the median survival time or the time (days) in which 50% of mussels have died) with increasing pollutant concentrations. However, in some experiments with low concentrations of contaminants a slight increase in LT50 has beeno bserved, possibly due to a hormetic effect. The method for determining SoS in mussels is being applied routinely to both toxicant-exposed mussels in laboratory studies and to mussels collected in national monitoring programmes from polluted environments and along pollution gradients. The added value of SoS in mussels is that this response measures the overall impact of multiple stressors on an organism. Thus, SoS responses can be quantitatively correlated to contaminant tissue concentrations, providing an integrated biological effect–chemical monitoring tool.Postprin

Towards an integrated approach for monitoring the effects of chemical contaminants in the Spanish coastal Mediterranean waters

Oral communicationIn the past twelve years, chemical monitoring surveys in Spanish Mediterranean coastal waters have developed from the use of native mussels to an integrated sampling of native and caged mussels, fish (red mullet) and sediment. In addition, the application of biological effect measurements (using biomarkers and bioassays) in the same matrices is being gradually arising. So far, biological measurements have comprised a suite of biomarkers in fish (EROD, Ala-D and AChE activities, Metallothionein content, DNA integrity and micronuclei abnormalities) and in mussels (Stress on Stress, lysosomal membrane stability, Metallothionein content, Micronuclei frequency, AChE and antioxidant enzymes) as well as the sea urchin embryotoxicity test with Paracentrotus lividus in sediment elutriates. Most of the driving forces behind these changes came from recommendations and Standard Operation Practices provided by expert organizations as MED POL, ICES, and OSPAR, and these changes have considerably increased the costs of monitoring. However, higher costs of intensive monitoring activities will allow contributing to a more realistic assessment of the quality and health status of the marine ecosystem. For this purpose quality assurance and the development of assessment criteria for the selected methods is a prerequisite. These requirements are necessary to meet national and international obligations (EU-MSFD, EU-WFD). Here, we present and discuss the integrated chemical-biological effect approach that is currently being proposed for implementation in the Spanish Mediterranean monitoring programme 2010-2012. The selected biological measurements, the assessment criteria obtained so far and quality assurance processes are discussed in terms of feasibility.The Spanish Mediterranean Biomonitoring Programs of chemical contamination (BMCW and BMIS programs) are conducted by the Instituto Español de Oceanografía (IEO) under the responsibility of the Ministry of Environment (MEDPOLIEO Project in 2006 and 2-ESMARME Project in 2010-2012)

Biomonitoring strategy to assess the effects of chemical pollution along the Iberian Mediterranean Coast: Present state and future development

oral presentationSince 2001, the Oceanographic Centre of Murcia (Spanish Institute of Oceanography, IEO) started to include selected biomarkers within the chemical pollution monitoring activities conducted along the Iberian Mediterranean coast. The main objectives of this biomonitoring programme are: (1) the determination of spatial distribution and temporal trends of chemical pollution in coastal and reference areas; (2) to seek evidence of detrimental biological effects and assess them over time. Sediment samples, feral fish (Mullus barbatus) and wild mussels (Mytilus galloprovincialis) are analysed yearly for selected pollutants (trace metals, organochlorinated compounds and polycyclic aromatic hydrocarbons) and selected biomarkers are measured in fish and/or mussels (EROD activity, metallothionein content, micronuclei frequency, genotoxic damages, acetylcholinesterase, stress on stress and lysosomal membrane stability). An integrated chemical-biological effect assessment approach is being conducted at four selected areas since 2006. Due to its geographical location, Spain contributes to both the CEMP and MEDPOL programmes and our future strategy will be focused to achieve the harmonization of criteria among different programmes and to meet the monitoring requirements in a cost-effective and cost-efficient way. The general strategy and methods of this biomonitoring programme together with some preliminary results and future development (use of caged mussels) are described and discussed.This Biomonitoring Programme was initially funded by the Spanish Institute of Oceanography, IEO (projects BIOMEJIMED I, BIOMEJIMED II and BIOMEJIMED III). Since November 2005 it is funded by Ministry of Environment (MEDPOLIEO project)

Assessing environmental quality status by integrating chemical and biological effect data: The Cartagena coastal zone as a case

En prensa1,953

Oral vaccination with heat inactivated Mycobacterium bovis activates the complement system to protect against tuberculosis

Tuberculosis (TB) remains a pandemic affecting billions of people worldwide, thus stressing the need for new vaccines. Defining the correlates of vaccine protection is essential to achieve this goal. In this study, we used the wild boar model for mycobacterial infection and TB to characterize the protective mechanisms elicited by a new heat inactivated Mycobacterium bovis vaccine (IV). Oral vaccination with the IV resulted in significantly lower culture and lesion scores, particularly in the thorax, suggesting that the IV might provide a novel vaccine for TB control with special impact on the prevention of pulmonary disease, which is one of the limitations of current vaccines. Oral vaccination with the IV induced an adaptive antibody response and activation of the innate immune response including the complement component C3 and inflammasome. Mycobacterial DNA/RNA was not involved in inflammasome activation but increased C3 production by a still unknown mechanism. The results also suggested a protective mechanism mediated by the activation of IFN-γ producing CD8+ T cells by MHC I antigen presenting dendritic cells (DCs) in response to vaccination with the IV, without a clear role for Th1 CD4+ T cells. These results support a role for DCs in triggering the immune response to the IV through a mechanism similar to the phagocyte response to PAMPs with a central role for C3 in protection against mycobacterial infection. Higher C3 levels may allow increased opsonophagocytosis and effective bacterial clearance, while interfering with CR3-mediated opsonic and nonopsonic phagocytosis of mycobacteria, a process that could be enhanced by specific antibodies against mycobacterial proteins induced by vaccination with the IV. These results suggest that the IV acts through novel mechanisms to protect against TB in wild boar

Meeting of the Ecosystem Approach Correspondence Group on on Pollution Monitoring (CorMon Pollution)

In accordance with the UNEP/MAP Programme of Work adopted by COP 21 for the biennium 2020-2021, the United Nations Environment Programme/Mediterranean Action Plan-Barcelona Convention Secretariat (UNEP/MAP) and its Programme for the Assessment and Control of Marine Pollution in the Mediterranean (MED POL) organized the Meeting of the Ecosystem Approach Correspondence Group on Pollution Monitoring (CorMon on Pollution Monitoring). The Meeting was held via videoconference on 26-27 April 2021. 2. The main objectives of the Meeting were to: a) Review the Monitoring Guidelines/Protocols for IMAP Common Indicator 18, as well as the Monitoring Guidelines/Protocols for Analytical Quality Assurance and Reporting of Monitoring Data for IMAP Common Indicators 13, 14, 17, 18 and 20; b) Take stock of the state of play of inter-laboratory testing and good laboratory practice related to IMAP Ecological Objectives 5 and 9; c) Analyze the proposal for the integration and aggregation rules for IMAP Ecological Objectives 5, 9 and 10 and assessment criteria for contaminants and nutrients; d) Recommend the ways and means to strengthen implementation of IMAP Pollution Cluster towards preparation of the 2023 MED Quality Status Report

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years